Muloz Dosage/Direction for Use

For mild persistent asthmatic, MULOZ (5 MG CHEWABLE TABLET) should be taken once daily. For moderate to severe asthma, MULOZ (5 MG CHEWABLE TABLET) should be taken once daily concomitantly with inhaled corticosteroids to provide additional benefit. The dose should be taken in the evening.
For allergic rhinitis, MULOZ (5 MG CHEWABLE TABLET) should be taken once daily. In patients who are not adequately controlled on the standard therapy according to specialized physicians' consideration, concomitant administration of MULOZ (5 MG CHEWABLE TABLET) may result in further improvement of symptoms. The time of administration may be individualized to suit patient needs. Patients with both asthma and allergic rhinitis should take only one dose in the evening.
Adults 15 years of age and older with asthma and/or allergic rhinitis: The dosage of adults 15 years of age and older is 10 mg once daily.
Pediatric patients 6 to 14 years of age with asthma and/or allergic rhinitis: The dosage of pediatric patients 6 to 14 years of age is 5 mg once daily.
For prevention of exercise-induced bronchoconstriction, MULOZ (5 MG CHEWABLE TABLET) should be administered at least 2 hours before exercise. Patients already taking MULOZ (5 MG CHEWABLE TABLET) for another indication, including chronic asthma, should not take an additional dose of the drug to prevent exercise-induced bronchoconstriction. All patients should have a short-acting β₂-agonist available for exacerbations of asthma that may occur after exercise despite Montelukast therapy.
Adults and adolescent 15 years of age and older: The usual dosage of adults and adolescent 15 years of age or older is 10 mg. An additional dose should not be taken within 24 hours of the previous dose.
Children 6-14 years of age: The usual dosage of children 6-14 years of age is 5 mg. An additional dose should not be taken within 24 hours of the previous dose.
General recommendations: The therapeutic effect of MULOZ (5 MG CHEWABLE TABLET) on parameters of asthma control occurs within one day. MULOZ (5 MG CHEWABLE TABLET) can be taken with or without food. Patients should be advised to continue taking MULOZ (5 MG CHEWABLE TABLET) while their asthma is controlled, as well as during periods of worsening asthma.
No dosage adjustment is necessary for pediatric patients, for the elderly, for patients with renal insufficiency, or mild-to-moderate hepatic impairment, or for patients of either gender.
Therapy with MULOZ (5 MG CHEWABLE TABLET) in relation to other treatments of asthma MULOZ (5 MG CHEWABLE TABLET) can be added to a patient's existing treatment regimen.
Reduction in concomitant therapy: Bronchodilator treatments: MULOZ (5 MG CHEWABLE TABLET) can be added to the treatment regimen of patients who are not adequately controlled on bronchodilator alone. When a clinical response is evident (usually after the first dose), the patient's bronchodilator therapy can be reduced as tolerated.
Inhaled corticosteroids: Treatment with MULOZ (5 MG CHEWABLE TABLET) provides additional clinical benefit to patients treated with inhaled corticosteroids. A reduction in the corticosteroid dose can be made as tolerated. The dose should be reduced gradually with medical supervision. In some patients, the dose of inhaled corticosteroids can be tapered off completely. MULOZ (5 MG CHEWABLE TABLET) should not be abruptly substituted for inhaled corticosteroids.